Showing 2301-2310 of 4117 results for "".
- Continuous Abrocitinib Use Linked to Better Long-Term AD Outcomes: Studyhttps://practicaldermatology.com/news/continuous-abrocitinib-use-linked-to-better-long-term-ad-outcomes-study/2473925/A new real-world study suggests that sustained abrocitinib treatment and adherence to the full 12-week induction phase improved outcomes and delay relapse in patients with moderate to severe atopic dermatitis (AD). "Although c
- No Link Between PCSK9 Inhibitors and Vitiligo Risk: Studyhttps://practicaldermatology.com/news/analysis-no-link-between-pcsk9-inhibitors-and-vitiligo-risk/2471859/New research published in the Journal of Investigative Dermatology shows no evidence linking PCSK9 inhibitors to an increased risk of vitiligo. Researchers exploring whether inhibiting PCSK9
- Biologics Linked to Lower Infection Risk in Older Psoriatic Patients: Studyhttps://practicaldermatology.com/news/biologics-linked-to-lower-infection-risk-in-older-psoriatic-patients-study/2471809/Biologics targeting interleukin (IL)-12, IL-23, and IL-17 were associated with lower rates of serious infection in older adults with psoriatic disease, according to a cohort study using Ontario health data. The study, publishe
- Lipid Metabolites Linked to Atopic Dermatitis Riskhttps://practicaldermatology.com/news/lipid-metabolites-linked-to-atopic-dermatitis-risk/2471714/A two-sample Mendelian randomization (TSMR) study has identified 13 lipid-related metabolite traits that influence the risk of developing atopic dermatitis (AD). Researchers examined genome-wide association study (GWAS) datase
- Colloidal Oatmeal Moisturizer in Managing Skin Microbiota: Studyhttps://practicaldermatology.com/news/colloidal-oatmeal-moisturizer-in-managing-skin-microbiota-study/2471650/A new in vitro study suggests a moisturizer containing colloidal oatmeal, patented filaggrin technology, niacinamide, and tocopheryl acetate selectively inhibits the growth and adhesion of Staphylococcus aureus (S. aureus) while promoting Staphylococcus epidermidis
- Upadacitinib Shows Superior Skin Clearance in Head and Neck Atopic Dermatitis Compared to Dupilumabhttps://practicaldermatology.com/news/Upadacitinib-Shows-Superior-Skin-Clearance-Head-Neck-Atopic-Dermatitis-Compared-Dupilumab/2471639/A numerically higher proportion of patients receiving upadacitinib achieved Eczema Area and Severity Index (EASI) 75/90/100 in the head and neck as early as 2 weeks after treatment was initiated compared with those receiving dupilumab in new Level Up study data present
- Remibrutinib Shows Positive Effects on Sleep, Daily Activities for CSU Patientshttps://practicaldermatology.com/news/Remibrutinib-Shows-Positive-Effects-Sleep-Daily-Activities-CSU-Patients/2471637/Remibrutinib’s impact on sleep deprivation and daily activities for patients with chronic spontaneous urticaria (CSU) were highlighted in a presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Robert Snyder, MD, FAAD, presented “Effect of Remib
- Journey Medical's Claude Maraoui to Speak in 'Fireside Chat' at ROTH Conferencehttps://practicaldermatology.com/news/Journey-Medicals-Claude-Maraoui-Speak-Fireside-Chat-ROTH-Conference/2471608/Journey Medical Corporation president and CEO Claude Maraoui will participate in a “fireside chat” Tuesday, March 18, at the 37th Annual ROTH Conference in Dana Point, California, the company announced. Maraoui’s session will be held at 12:30 p.m. PT, and a webcast will be available for ap
- Benzene Update at AAD Discusses Both Regulations and Health Riskshttps://practicaldermatology.com/news/Benzene-Update-AAD-Discusses-Both-Regulations-Health-Risks/2471605/Christopher Bunick, MD, PhD, FAAD, made waves at the 2024 American Academy of Dermatology (AAD) Annual Meeting with his presentation about benzene in benzoyl peroxide (BPO) products for acne treatments. At the 2025 AAD Annual Meeting in Orlando, Florida, Dr. Bunick provided an update on the resea
- New Baricitinib AA Data for Adolescents Could Be 'Game-Changing'https://practicaldermatology.com/news/New-Baricitinib-AA-Data-Adolescents-Could-Be-Game-Changing/2471600/Patients ages 12 to under 18 with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at Week 36 in the Phase 3 BRAVE-AA-PEDS study, presented as a late-breaker at the 202